- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04538976
Copd Exacerbation and Pulmonary Hypertension Trial (CODEX-P)
August 31, 2023 updated by: Chronic Obstructive Pulmonary Disease Trial Network, Denmark
This trial will investigate whether patiens admitted with an acute exacerbation of chronic obstructive lung disease and pulmonary hypertension will benefit from a targeted pharmacological treatment.
Study Overview
Detailed Description
During admittance due to acute exacerbation of chronic obstructive lung disease will patience have an echocardiography to examine their pulmonary pressure.
If patient have a tricuspidal return gradient above 40 mmHg, they will receive treatment with a phosphordiesterase-5-inhibitor, Sildenafil.
Study Type
Interventional
Enrollment (Estimated)
2
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Pradeesh Sivapalan, PhD
- Phone Number: 004538673513
- Email: pradeesh.sivapalan.01@regionh.dk
Study Locations
-
-
-
Copenhagen, Denmark
- Recruiting
- Herlev-Gentofte Hospital
-
Contact:
- Jens-Ulrik Jensen, MD, PhD
-
Copenhagen, Denmark
- Not yet recruiting
- Bispebjerg University Hospital
-
Contact:
- Lars Pedersen
-
Copenhagen, Denmark
- Not yet recruiting
- Hvidovre Hospital
-
Contact:
- Charlotte Ulrik
-
Hillerød, Denmark
- Not yet recruiting
- Nordsjællands Hospital
-
Contact:
- Andrea Browatzki
-
Odense, Denmark
- Recruiting
- Odense Universitetshospital
-
Contact:
- Christian B Laursen, Prof.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- COPD verified by specialist and spirometry
- Admitted with the diagnosis "acute exacerbation of COPD"
- TR-gradient ≥40 mmHg verified by specialist and echocardiography
- Informed consent
Exclusion Criteria:
- Known pulmonal hypertension
- Known heart disease which affects the pump function of the heart
- Men <40 years
- Women <55 years
- Not-menopauseal women <55 years (Menopause is defined as no menstruation within 12 months.)
- Severe mental illness which significantly complicates cooperation
- Severe language difficulties which significantly complicates cooperation
- known allergy to Sildenafil
- Sildenafil consumption ≥50 mg / week due to other indications
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Control
Patients in the control group will receive standard care.
|
|
Active Comparator: Sildenafil
Patients in the Sildenafil group will receive standard care and targeted Sildenafil-treatment.
|
Sildenafil in standard dosage
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time alive and out of hospital
Time Frame: 365 days
|
365 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time to "prednisolon and/or antibiotica"-needing exacerbation of COPD or death
Time Frame: 365 days
|
365 days
|
Death within 90 days
Time Frame: 90 days
|
90 days
|
Death within 1 year
Time Frame: 365 days
|
365 days
|
Alive and without exacerbation of COPD on day 365
Time Frame: 365 days
|
365 days
|
Clinical cure
Time Frame: 14 days
|
14 days
|
Number of readmissions due to exacerbations of COPD
Time Frame: 365 days
|
365 days
|
Number of days with non-invasive ventilation (NIV) or respirator during admittance
Time Frame: 14 days
|
14 days
|
Delta Pa(O2)
Time Frame: 4 days
|
4 days
|
Delta Pa(CO2)
Time Frame: 4 days
|
4 days
|
Delta(pH)
Time Frame: 4 days
|
4 days
|
Change in FEV1
Time Frame: 90 days
|
90 days
|
Change in COPD Assesment Test (CAT)
Time Frame: 29 days
|
29 days
|
Change in Body Mass Index (BMI)
Time Frame: 90 days
|
90 days
|
Delta(TR-gradient)
Time Frame: 4 days
|
4 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 1, 2020
Primary Completion (Estimated)
October 31, 2023
Study Completion (Estimated)
October 31, 2025
Study Registration Dates
First Submitted
August 30, 2020
First Submitted That Met QC Criteria
August 30, 2020
First Posted (Actual)
September 4, 2020
Study Record Updates
Last Update Posted (Actual)
September 1, 2023
Last Update Submitted That Met QC Criteria
August 31, 2023
Last Verified
August 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Respiratory Tract Diseases
- Lung Diseases
- Hypertension
- Hypertension, Pulmonary
- Molecular Mechanisms of Pharmacological Action
- Vasodilator Agents
- Urological Agents
- Enzyme Inhibitors
- Phosphodiesterase Inhibitors
- Phosphodiesterase 5 Inhibitors
- Sildenafil Citrate
Other Study ID Numbers
- Study_protocol_CODEX-P_ver2_1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
We have not yet decided to share IPD.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Exacerbation of COPD
-
Hospital Quiron Sagrado CorazonNot yet recruiting
-
Alung TechnologiesTerminatedAcute Exacerbation of COPDUnited States
-
Assistance Publique - Hôpitaux de ParisBioMérieuxRecruiting
-
Postgraduate Institute of Medical Education and...Completed
-
omar hasham mohamedRecruiting
-
Ataturk UniversityNot yet recruitingCOPD Exacerbation Acute
-
Versailles HospitalRecruiting
-
University Hospital, MahdiaUnknownAcute Exacerbation CopdTunisia
-
Inonu UniversityTerminatedCOPD Acute Exacerbation
-
Saglik Bilimleri UniversitesiGulhane Training and Research HospitalNot yet recruitingCOPD Exacerbation AcuteTurkey
Clinical Trials on Sildenafil
-
University of PennsylvaniaWalter Reed National Military Medical CenterRecruiting
-
Rambam Health Care CampusUnknown
-
Duke UniversityNational Heart, Lung, and Blood Institute (NHLBI); PfizerCompleted
-
Northwestern UniversityCompletedHand Foot Skin ReactionUnited States
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedErectile DysfunctionSingapore
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Completed
-
The Cleveland ClinicCompletedPulmonary Hypertension | Diffuse Parenchymal Lung DiseaseUnited States
-
iX Biopharma Ltd.Linear Clinical ResearchCompletedErectile DysfunctionAustralia
-
Rigshospitalet, DenmarkGlostrup University Hospital, CopenhagenCompletedBecker Muscular DystrophyDenmark
-
N4 Pharma UK Ltd.BDD Pharma LtdCompleted